CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç° ¹× ¼­ºñ½ºº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By Product & Service (Kits & Reagents, Cell Line Engineering), By Application (Biomedical, Agricultural), By End Use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1611209
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,443,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,862,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,700,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

CRISPR°ú Cas À¯ÀüÀÚ ½ÃÀå ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ »õ·Î¿î º¸°í¼­¿¡ µû¸£¸é, ¼¼°è CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 113¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2030³â µ¿¾È 16.12%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿øÇÙ »ý¹° Áø´Ü ¹× ÁøÈ­ ºÐ¼® Æò°¡¿¡¼­ CRISPR-Cas ½Ã½ºÅÛÀÇ »ç¿ëÀº À¯Àüü ÆíÁý ºÎ¹®ÀÇ °³¹ß·Î ÀÎÇØ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀÇ Àû¿ëÀ¸·Î ½±°í Àú·ÅÇÑ ºñ¿ëÀ¸·Î À¯ÀüÀÚ¸¦ ÆíÁýÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. À¯Àüü ÆíÁýÀº »ý¹° ÀÇÇÐ ¿¬±¸¿¡¼­ Å« ÁøÀüÀ» ÀÌ·ç¾úÀ¸¸ç, ÇöÀç ÃÖ÷´Ü ±â¼ú µ¿ÇâÀº ´Ù¾çÇÑ À¯ÀüÀû ¹× ºñÀ¯ÀüÀû ÁúȯÀÇ ¹Ì·¡ Ä¡·áÀÇ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù.

CRISPR/Cas9¸¦ ÅëÇÑ À¯ÀüÀÚ ¹× À¯Àüü ÆíÁý ±â¼úÀ» »ç¿ëÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó À¯ÀüÀÚ Ç¥ÀûÈ­¸¦ À§ÇÑ º¸´Ù È¿°úÀûÀÎ ¹æ¹ýÀÇ °³¹ß ¹× ±¸Çö°ú À¯ÀüÀÚ ÆíÁý Á¶·ùÀÇ »ý»êÀÌ ¿ëÀÌÇØÁ³½À´Ï´Ù. 2021³â 2¿ù Frontiers¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é, CRISPR/Cas9´Â °¡±Ý·ù »ê¾÷¿¡¼­ Cas9´Â °¡±Ý·ù »ê¾÷¿¡¼­ À¯ÀüÀÚ ÆíÁýÀ» À§ÇÑ °­·ÂÇϰí Áß¿äÇÑ µµ±¸°¡ µÇ¾ú½À´Ï´Ù. ¿©·¯ ºÐ¾ß¿¡¼­ÀÇ ÀÀ¿ë °¡´É¼ºÀº ÀÌ ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµÇ¸ç, COVID-19ÀÇ ¹ß»ýÀ¸·Î ÀÎÇØ ¿¬±¸ÀÚµéÀº ÀÌ ±â¼úÀ» ÀÌ¿ëÇÑ COVID-19 ºÐÀÚÁø´Ü µµ±¸ÀÇ °³¹ß¿¡ ÁßÁ¡À» µÎ°Ô µÇ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 3¿ù ½Ì°¡Æ÷¸£ ³­¾ç°ø´ë(Nanyang Technological University) ¿¬±¸ÁøÀº CRISPRÀ» ±â¹ÝÀ¸·Î 30ºÐ ¸¸¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Â COVID-19 Áø´ÜŰƮ¸¦ °³¹ßÇß½À´Ï´Ù.

ÀÌ Å×½ºÆ®´Â ¹ÙÀÌ·¯½º°¡ º¯ÀÌµÈ ÈÄ¿¡µµ ¹ÙÀÌ·¯½º¸¦ ¹ß°ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ´Ù¸¥ ÁÖ¿ä ±â¾÷µéÀÌ ÀÌ ±â¼úÀ» Ȱ¿ëÇϵµ·Ï ´õ¿í ÀÚ±ØÇÏ¿© »ê¾÷ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â¼úÀº ÀÇ·á ¹× ±âŸ ¿ëµµ·Î Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¯ÀüÀÚ ÆíÁý ±â¼ú ƯÇã °æÀïÀº ÀÌ ±â¼úÀÇ »õ·Î¿î »ó¾÷Àû ÀÀ¿ëÀ» °³¹ßÇÏ·Á´Â Çаè¿Í »ý¸í°øÇÐ ±â¾÷µéÀÌ ´Ã¾î³²¿¡ µû¶ó ´õ¿í Ä¡¿­ÇØÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¸Ó½Å·¯´× ±â¼úÀÇ È°¿ëÀ¸·Î ÀÌ ±â¼úÀÌ ¹ßÀüÇÒ °¡´É¼ºµµ Å®´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 8¿ù Synthego´Â ±â´ÉÀû ½ºÅ©¸®´× ½ÇÇè¿¡ Á÷Á¢ »ç¿ëÇÒ ¼ö ÀÖµµ·Ï CRISPR·Î ÆíÁýµÈ ¼¼Æ÷¸¦ ¹è¿­ÇÏ¿© CRISPR¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇÏ´Â ÃÖ÷´Ü ¼­ºñ½ºÀÎ Engineered cell libraries¸¦ Ãâ½ÃÇß½À´Ï´Ù.

Áúº´ ¿¬±¸¿¡ÀÇ Àû¿ëÀÌ ±â´ëµË´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº À¯ÀüÀÚ ÆíÁý ¿öÅ©Ç÷οìÀÇ °¢ ´Ü°è¿¡ ¸Â´Â µµ±¸¿Í ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¿©·¯ µµ±¸, ¼­ºñ½º ¹× °³¼±µÈ ÇÁ·Î¼¼½º¸¦ ÅëÇÕÇÏ¿© ¿¬±¸ ½ÇÇèÀ» ´õ ºü¸£°í ÀûÀº ³ë·ÂÀ¸·Î ¿Ï·áÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷µéÀº CRISPR &Cas9 À¯ÀüÀÚ ÆíÁý Á¢±Ù¹ýÀÇ ¿¬±¸ °³¹ßÀ» Áö¿øÇϱâ À§ÇØ ¸¹Àº ÀÚ±ÝÀ» Á¶´ÞÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 4¿ù Vertex Pharmaceuticals´Â CRISPR Therapeutics¿Í Á¦ÈÞÇÏ¿© ¼öÇ÷ ÀÇÁ¸¼º º£Å¸ ÁöÁßÇØºóÇ÷ ¹× °â»óÀûÇ÷±¸Áõ(SCD)ÀÇ Ä¡·á ¿É¼ÇÀÌ µÉ ¼ö ÀÖ´Â CTX001À̶ó´Â »õ·Î¿î CRISPR/Cas9 ±â¹Ý À¯ÀüÀÚ ÆíÁý Ä¡·áÁ¦¸¦ °³¹ß ¹× Á¦Á¶Çß½À´Ï´Ù. 2020³â 1¿ù, Mammoth Biosciences´Â Ä¡·á ¹× Áø´Ü ¸ñÀûÀÇ Â÷¼¼´ë CRISPR Á¦Ç°À» °³¹ßÇϱâ À§ÇØ 4,500¸¸ ´Þ·¯ÀÇ ÀÚ±ÝÀ» Á¶´ÞÇß½À´Ï´Ù. ÀÌ ÀÚ±ÝÀº ȸ»çÀÇ CRISPR À¯ÀüÀÚ ±â¹Ý Áø´Ü Æ÷Æ®Æú¸®¿À¸¦ °³¹ßÇÏ´Â µ¥ »ç¿ëµÉ ¿¹Á¤ÀÔ´Ï´Ù.

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå º¸°í¼­ ÁÖ¿ä ³»¿ë

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå Á¦Ç°¡¤¼­ºñ½º ºñÁî´Ï½º ºÐ¼®

Á¦5Àå ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦6Àå ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦7Àå Áö¿ª ºñÁî´Ï½º ºÐ¼®

Á¦8Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

CRISPR And Cas Genes Market Growth & Trends:

The global CRISPR and Cas genes market size is expected to reach USD 11.33 billion by 2030, growing at a CAGR of 16.12% from 2025 to 2030, according to a new report by Grand View Research, Inc. The use of CRISPR-Cas systems in diagnostics and the assessment of evolutionary analysis in prokaryotes has significantly increased, owing to the developments in the field of genome editing. The application of this technology enables easy and cost-efficient editing of genes. Genome editing has made a significant advancement in biomedical research, with the present trend of cutting-edge techniques paving the way for the future treatment of different genetic and non-genetic disorders.

The development and implementation of more effective ways for gene targeting and the generation of gene-edited avian species have been facilitated by the availability of the CRISPR/Cas9-mediated gene and genome editing technology. According to an article published on Frontiers in February 2021, CRISPR/Cas9 has become a robust and important tool for gene editing in the poultry industry. Potential applications in several fields would further boost the demand for this technology. The COVID-19 outbreak shifted the researcher's emphasis to the development of COVID-19 molecular diagnostic tools based on this technology. For instance, in March 2021, Nanyang Technological University researchers in Singapore created a COVID-19 test based on CRISPR that provides results in 30 minutes.

Even after the virus has mutated, this test still discovers it. This would further encourage the other key players to leverage this technique, thereby driving the industry's growth. This technology is increasingly being used for several medical and other applications. Competition over patents for such a gene-editing technology is expected to grow, as more academic institutions and biotech companies attempt to develop new commercial applications of this technology. In addition, there is a lot of potential for this technique to advance with the use of machine learning technologies. For instance, in August 2022, Synthego launched engineered cell libraries, a cutting-edge service that expands access to CRISPR by giving arrayed CRISPR-edited cells for use directly in functional screening experiments.

It has potential applications in disease research. Key players offer tools and solutions for each step of the gene editing workflow. Integrating several tools, services, and improved processes makes it possible to complete research experiments rapidly and with little effort. Moreover, key players have raised significant funding to support the R&D of the CRISPR & Cas9 gene-editing approach. For instance, in April 2021, Vertex Pharmaceuticals collaborated with CRISPR Therapeutics to develop and manufacture a new CRISPR/Cas9-based gene editing therapy called CTX001, a potential therapeutic option for transfusion-dependent beta-thalassemia and Sickle Cell Disease (SCD). In January 2020, Mammoth Biosciences raised USD 45 million to develop next-gen CRISPR products for therapeutics & diagnostics purposes. This would further be used to develop the company's CRISPR genes-driven diagnostics portfolio.

CRISPR And Cas Genes Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Product & Service Business Analysis

Chapter 5. Application Business Analysis

Chapter 6. End Use Business Analysis

Chapter 7. Regional Business Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â